Header1.jpg

About us: Partners

Collaborations are vital to the success of our business at Igyxos.

We have established alliances with the following organizations.

MERCK_LOGO_Blue_RGB.png

In September 2020, Selexis and Igyxos announced a service agreement to develop Igyxos’ first-in-class monoclonal antibody (mAb) drug candidate for the treatment of human infertility. Under the agreement, Igyxos will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance the program in human trials.